Ezcol Overview
- Founded
- 2007
- Status
- Private
- Latest Deal Type
- Angel
- Investors
- 1
Ezcol General Information
Description
Developer of an innovative drug designed to lower cholesterol. The company's cholesterol-diminishing bacterium keeps cholesterol in check, enabling patients to reduce the risk of heart disease and strokes.
Contact Information
Website
Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- Lunerkampweg
- 5245 NB Hertogenbosch
- Netherlands
+31 073 000 0000
Ezcol Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Angel (individual) | 01-Mar-2020 | Completed | Generating Revenue | |||
| 1. Accelerator/Incubator | 30-Nov-2008 | Completed | Generating Revenue |
Ezcol Executive Team (2)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Rob Suters | Co-Founder & Chief Executive Officer |
Ezcol Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| ESA Space Solutions | Accelerator/Incubator | Minority | 000 0000 | 000000 0 |